Ascendis Pharma Shares Rise 2% to $221.31
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
A rumor regarding Ascendis Pharma was highlighted in Ben Harrington's M&A-focused Betaville blog, contacts tell The Fly. Shares of Ascendis are up $4.65, or 2%, to $221.31 in morning trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASND
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 267.50 USD with a low forecast of 240.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
Continue Reading
Ascendis Pharma (ASND) Stock Rises 7.5% Amid Takeover Speculation
- Takeover Rumors: Ascendis Pharma (ASND) shares rose 7.5% amid speculation that a Switzerland-based pharmaceutical company and another European firm are eyeing the company, indicating market optimism about its future prospects.
- Market Capitalization: With a market cap of $13.3 billion, Ascendis Pharma reflects investor recognition of its potential acquisition value, highlighting its competitiveness in the biopharmaceutical sector.
- Investor Interest: Traders noted that a Betaville 'uncooked' alert circulated on Thursday, further igniting market interest in Ascendis, which may attract more investors to its stock.
- Financial Performance: Ascendis Pharma reported a GAAP EPS of -€1.00 and revenue of €213.63 million, and while current financial performance is weak, the takeover rumors may enhance market expectations for its future profitability.
Continue Reading